FDA needs another trial of Onconase in mesothelioma
This article was originally published in Scrip
Executive Summary
Alfacellwill need to conduct another clinical trial in malignant mesothelioma with its experimental drug candidate Onconase (ranpirnase) before it will be able to file it with the USFDA, the company said after a pre-NDA meeting with the agency.